Miles Wang, an OpenAI researcher, is in talks to raise $200M at a $2bn valuation for an AI drug-discovery startup that has no name or product yet.

Lightspeed is in discussions to lead the funding round, sources say.

Miles Wang, an OpenAI researcher, is in talks to raise $200M at a $2bn valuation for an AI drug-discovery startup that has no name or product yet.